Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 576 participants.
Also called NCT03658031
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 576 participants
- Sponsor
- Registry
-
NCT03658031
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Qatar
- Registry status
- Unknown status
Technical summary
Registry record NCT03658031. Randomized; no masking; primary purpose treatment. Start 2019-03-01 (anticipated); primary completion 2020-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
- Condition
- PreDiabetes
- Condition
- Myocardial Infarction
- Condition
- T2DM (Type 2 Diabetes Mellitus)
- Condition
- CVD
- Intervention (Drug)
- Dapagliflozin 10mg
- Lead sponsor
- Hamad Medical Corporation
Record details
- Record id
cardio:ct-nct03658031- Content hash
6515e5ed8e4c3624bca0a908962785b5c172b3e2df8c43fcd007c6375d2f4a85